Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS Vaccine Development

1 Jul 2005

Abstract excerpt

Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Immune responses and vaccinations
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16022774
DOI: 10.3201/1107.050219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS Vaccine DevelopmentPMID 16022774Read ↗

SARS Vaccine DevelopmentSemantic proximity Read ↗

Receptor-binding domain as a target for developing SARS vaccines.Semantic proximity Read ↗

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.Semantic proximity Read ↗

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccineSemantic proximity Read ↗

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read ↗

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2Semantic proximity Read ↗

Cellular and humoral immunogenicity of a candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1Semantic proximity Read ↗

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patientsSemantic proximity Read ↗

SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responsesSemantic proximity Read ↗

Preclinical Study of DNA Vaccines Targeting SARS-CoV-2Semantic proximity Read ↗

Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine DesignSemantic proximity Read ↗

Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine CandidatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.